BioInvent granted US patent for the F.I.R.S.T.™ antibody screening technology
Monday, 11 November 2013
BioInvent International AB (OMXS: BINV) today announces that it has
been granted a US patent for its antibody and concomitant target
discovery technology F.I.R.S.T.™.
Traditional drug discovery methods involve the identification of drugs
candidates that bind to known disease targets. The F.I.R.S.T.™
technology is a novel and unique discovery method, which allows for
antibodies and disease targets to be identified simultaneously.
BioInvent has used F.I.R.S.T.™ successfully in several proprietary
discovery projects and offers F.I.R.S.T.™ as well as traditional
antibody discovery screening to commercial partners.
“With billions of binders available in the libraries and
state-of-the-art in vitro and in vivo cancer and immunological assays,
we can discover antibodies with the very best properties for onward
development.” Said Björn Frendeus, VP
Based on press release – scancomark.com
Did you spot any error(s) or had any problem with the above article. Please contact us